XML 41 R23.htm IDEA: XBRL DOCUMENT v3.3.0.814
Collaboration and Other Agreements, Takeda Pharmaceutical Company Limited (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 9 Months Ended
May. 31, 2014
Sep. 30, 2015
Sep. 30, 2014
Sep. 30, 2015
Sep. 30, 2014
Dec. 31, 2014
Collaboration And Other Agreements [Line Items]            
Deferred revenue current   $ 7,163   $ 7,163   $ 14,248
Deferred revenue non-current   11,889   $ 11,889   16,472
Takeda Pharmaceutical Company Limited [Member]            
Collaboration And Other Agreements [Line Items]            
Non-refundable upfront payment $ 15,000          
Agreement beginning date       May 2014    
Potential license option fee   15,000   $ 15,000    
Upfront fee allocated to agreement 10,000          
Expected period of development       24 months    
Recognized revenue under agreement   1,300 $ 1,300 $ 6,800 $ 1,700  
Deferred revenue   3,300   3,300   7,100
Deferred revenue current   3,300   3,300   5,000
Deferred revenue non-current   0   0   $ 2,100
Revenue Recognition, Milestone Method, Revenue Recognized       3,000    
Additional Potential Sales Milestone Payments Under Agreement   375,500   375,500    
Additional Potential Clinical And Regulatory Milestone Payments Under Agreement   93,000   $ 93,000    
Takeda Pharmaceutical Company Limited [Member] | Research Collaboration And License Option Agreement [Member]            
Collaboration And Other Agreements [Line Items]            
Agreement beginning date       September 2014    
Upfront fee allocated to agreement $ 5,000          
Research and development services revenue   $ 500   $ 1,100